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ABSTRACT Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system 
(CNS). Proteins of the immune system, as well as proteins that are involved in the infiltration of activated im-
mune cells in the CNS, play an important role in the pathogenesis of MS. We investigated the association and 
linkage with MS of the following immune-system genes polymorphisms: HLA-DRB1, CTLA4, TGFB1, IL4, CCR5 
and RANTES, as well as of the matrix metalloproteinase 9 (MMP9) and tissue inhibitor of metalloproteinase  1 
(TIMP1) genes polymorphisms. For this purpose we used the transmission disequilibrium test (TDT). The group 
investigated was comprised of 100 nuclear families of Russian ethnicity, each consisting of an affected offspring 
and his nonaffected parents. It was found that HLA-DRB1*15 allele and MMP9*-1562C allele were transmitted 
from healthy heterozygous parents to affected children more frequently than alternative alleles (p  =  0.02 and 
p  =  0.04, respectively). Another family-based method, AFBAC (affected family-based control), showed MS as-
sociation with HLA-DRB1*15, but not with the MMP9*-1562C allele.
KEYWORDS functional genomics, human, multiple sclerosis, genotyping, CCR5 gene, CTLA4 gene, HLA-DRB1 
gene, IL4 gene, MMP9 gene, RANTES gene, TGFB1 gene, TIMP1 gene, allelic polymorphism, TDT, AFBAC.
ABBEVIATIONS MS – multiple sclerosis; PCR – polymerase chain reaction; CNS – central nervous system; AFBAC 
(affected family-based control) – the method of family analysis, in which the control group consists of the alleles, 
that were not transmitted from parents to affected children; CCR5 (CCR5) – CC chemokine receptor  5 (its gene); 
CTLA4 (CTLA4) – cytotoxic T lymphocyte antigen-4 (its gene); HLA-DRB (HLA-DRB1) – β chain of human 
HLA-DR antigen (its gene  1); IL-4 (IL4) – interleukin-4 (its gene); MMP (MMP) – matrix metalloproteinase (its 
gene); RANTES (RANTES) – chemokine regulated on activation, normal T  cell expressed and secreted (its gene); 
SNP – single-nucleotide polymorphism; TDT – transmission disequilibrium test; TGFβ1 (TGFB1) – transforming 
growth factor β1 (its gene); TIMP (TIMP) – tissue inhibitor of matrix metalloproteinases (its gene).
INTRODUCTION
Multiple sclerosis (MS) is a severe inflammatory dis-
ease of the central nervous system (CNS) which typi-
cally develops in the young adults and subsequently 
leads to disability. This disease has a complex etiology 
with both genetic and environmental factors [1]. The 
ways MS is inherited are typical for polygenic diseases; 
their development is conditioned by the joint contri-
bution of a number of polymorphic genes [2]. The elici-
tation of the genetic risk factors for MS may help shed 
light on the mechanisms underlying the pathogenesis 
of this disease and open new possibilities for its pre-
vention and treatment. In spite of the large number of 
studies that have investigated the genetics of MS, the 
search for MS-associated genes remains a challenge. 
This is due to the nature of the disease, for which ge-
netic heterogeneity is typical, particularly in different 
ethnic groups, as well as the absence of a main gene. 
On the other hand, the search for the risk factors for 
MS is made more difficult by the limitations of the 
major analysis approaches. The MS genome linkage 
analysis has yielded little information because of its 
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low sensitivity [3]. When analyzing genetic associa-
tions with MS using the case–control method, there is 
a low reproducibility of the results: a factor related to 
the ethnic heterogeneity of the healthy and affected 
groups under consideration and the influence of envi-
ronmental factors [4].
The methods that use a family analysis of associa-
tions allow to eliminate or to minimize the influence 
of the ethnic heterogeneity of groups of patients and 
unrelated healthy controls, as well as the effect of en-
vironmental factors [5]. One such method is the trans-
mission disequilibrium test, TDT [6], which is based on 
the analysis of marker allele or haplotype transmission 
from heterozygous parents to affected children. The 
TDT method has already been used to analyze the link-
age and association of the alleles of a number of candi-
date genes with MS among various ethnicities [7–10], 
including Russians (our studies [11, 12]). This method is 
now being used not only to analyze the contribution of 
individual genes to the MS development, but also as a 
tool in a full genome search [13–15]. Family data have 
also been used to carry out the association analysis us-
ing the affected family-based control (AFBAC) method. 
According to this data, the control group is composed of 
a set of alleles from healthy parents which were not 
transmitted to affected children (one allele from each 
parent) [16]. This method was used to analyze MS sus-
ceptibility in Italy [17, 18], Great Britain [19], Belgium 
[20], and France [21]. Each of these methods of family 
analysis has advantages and drawbacks. Thus, AFBAC 
is a more powerful method as compared with TDT, 
while TDT makes it possible to completely eliminate 
the population stratification effects [22].
In this study, we analyzed MS linkage and asso -
ciation of HLA-DRB1, CTLA4, TGFB1, IL4, CCR5, 
RANTES, MMP9, and TIMP1 genes in ethnic Russians 
on the basis of family data using the TDT and AFBAC 
methods.
Numerous data suggest the involvment of these 
genes in the immunopathogenesis of MS as an autoim-
mune disease [2]. A repeatedly confirmed fact is that 
particular alleles (depending on the population ethnic-
ity) of the HLA-DRB1 gene class II are involved in the 
development of MS. This gene encodes the β-chain of 
the heterodimer, which presents the antigen to CD4+ 
T-lymphocytes. Our study also includes the  CTLA4 
gene encoding the cytotoxic T-lymphocyte antigen  4 
(CTLA4 or CD152) – the T-lymphocytes costimulation 
receptor, which is an important negative regulator of 
the T cells activity and participates in the maintenance 
of the peripheral T  cell tolerance [23].
Cytokines are believed to play the key role in the de-
velopment and regulation of the autoimmune inflam-
matory process that is typical of MS. In addition to the 
data obtained by the analysis of MS linkage and asso-
ciation with alleles of proinflammatory cytokine genes 
[12], the genes of anti-inflammatory cytokines  TGFβ1 
and IL-4 – were also considered in this study. Cytokine 
TGFβ1 is secreted by numerous cell types, including 
regulatory T- lymphocytes, astrocytes, and endothelial 
cells; while cytokine IL-4 is secreted mainly by acti-
vated Th2 -cells. These cytokines can be detected in   
the brain tissues at the remission stage; their level be-
ing reduced upon active progressive multiple sclerosis 
[24].
The key stage in the development of the immun-
opathological process upon MS is the disturbance of 
the hematoencephalic barrier and T and B cells pen-
etration into the CNS. The stimulation and direction 
of migration of different cell classes  is to a large ex-
tent determined by chemokines. Our study includes 
genes of RANTES (Regulated on Activation Normal 
T cells Expressed and Secreted) chemokine, which is 
an attractant for lymphocytes and monocytes, and of 
its receptor CCR5. The levels of RANTES and  CCR5 
sharply increase on lymphocytes, macrophages, and 
microglias in the demyelination  lesions upon MS acute 
attack [25].
The penetration of immune cells into the CNS is ac-
companied by the type  IV collagen degradation, which 
is the extracellular matrix major constituent. The ma-
trix metalloproteinases (MMPs) play the key role in this 
barrier penetration. The MMPs are involved in vari-
ous stages of MS pathogenesis: they participate in the 
local damaging of the hematoencephalic barrier and 
perivascular lymphocytes infiltration, in the damaging 
of myelin sheath and in the formation of the demyeli-
nation lesions and axonal death [26]. One of the major 
metalloproteinases, MMP9, is expressed by perivas-
cular mononuclear cells of white matter and, together 
with other MMPs, is associated with monocytes and as-
trocytes in the demyelination lesions.
MMP activity is controlled by tissue inhibitors of ma-
trix metalloproteinases (TIMPs), while the TIMP1 level 
in the cerebrospinal fluid of MS patients was found to 
be decreased [26]. Considering these data, the MMP9 
and  TIMP1 genes were included in our study.
The genomic typing of 18   allelic groups of  the 
HLA-DRB1 gene and the following single-nucleotide 
polymorphisms (SNPs) 49A>G of the  CTLA4 gene; 
–509C>T of the TGFB1 gene; –590C>T of IL4 gene; 
–403G>A of the  RANTES gene; –1562C>T of the 
MMP9 gene; 372C>T of the TIMP1 gene; as well as 
of the deletion-insertion polymorphism CCR5 (w→d) 
(“wild type” → deletion of 32  bp), was carried out for 
Russian MS patients and their healthy parents, fol-
lowed by the analysis of genetic predisposition to MS 
using the TDT and AFBAC methods. Selection of the RESEARCH ARTICLES
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polymorphic regions for the analysis proceeded from 
the data on their influence on the level and/or activity 
of the encoded proteins Thus, the functional roles of 
the  DRB1 gene alleles in antigen presentation and the 
consequences of deletion in the CCR5 gene resulting in 
the production of the CCR5 inactive protein are well 
known. With regard to the SNPs analysis, rare alle-
les of the TGFB1, IL4, RANTES, and MMP9 genes are 
associated with the enhanced production of the pro-
tein [27–30], whereas the expression of the encoded 
protein on the cell surface is increased in the carriers 
of the allele A of the CTLA4 gene [31]. SNP 372C>T 
of the TIMP1 gene is the only exception with no data 
available.
EXPERIMENTAL
The object of investigation
The study was performed using peripheral blood sam-
ples obtained from members of 104 nuclear families, 
each of them comprising MS patients and their healthy 
parents. The blood samples were collected at the Re-
search Center of Children Health, Russian Academy of 
Medical Sciences, and at the Multiple Sclerosis Moscow 
City Center . The MS diagnosis was done according to 
McDonald’s criteria [32]. There were 46 male patients 
and 58 female ones; all patients experienced the onset 
of MS before the age of 35. The mean MS onset age was 
18  ±  8 years. The disease had a relapsing–remitting 
course in 102 patients and a primary progressive course 
in two patients. All patients and their healthy relatives 
were residents of the Moscow region and belonged to 
Russian ethnicity. All families provided their informed 
consent for participation in the study.
DNA extraction and genotyping
Genomic DNA was extracted from mononuclear blood 
cells using a phenol–chloroform mixture according to 
the standard procedure [33].
Table  1 lists the polymorphic regions of the analyzed 
genes, PCR-based genotyping methods, and the prim-
ers used. Typing of the HLA-DRB1 gene was carried 
out by allele-specific PCR, in accordance with the rec-
ommendations of the manufacturer of the kit (AO DNA 
Technology, Russia) used to identify the allele groups 
corresponding to serological specificities from DR1 to 
DR18.
 
Statistical analysis
Linkage and association of the genes with MS was 
studied using TDT [6] with χ2 criterion. Haploview  3.32 
free software was used for analysis of bi-allelic poly-
morphism, and FBAT [35] was used for analysis of 
multi-allelic polymorphism of the HLA-DRB1 gene 
and polymorphism of the TIMP1 gene located on the 
X-chromosome. We analyzed the transmission of gene 
alleles from parents to affected children in families 
with at least one heterozygous parent. The difference 
between the frequencies of transmitted and non-trans-
mitted alleles was considered significant at χ2  >  3.8 
(p  < 0.05). In order to analyze MS association with alle-
les of the studied genes using the AFBAC method, the 
control group was made up of the alleles of both par-
ents which were not transmitted to the affected chil-
dren. The probability value (p) was assessed with the 
two-sided Fischer’s exact test using GraphPAD InStat 
1.12a software.
The discrepancy in the observed distribution of gen-
otype frequencies in the groups of patients and their 
healthy parents from the Hardy–Weinberg equilib-
rium was analyzed by the expectation maximization 
algorithm, using Haploview  3.32.
RESULTS AND DISCUSSION
All the members of the 104  nuclear families were gen-
otyped for the polymorphisms shown in Table  1. Four 
families, for which the paternity was not confirmed by 
the results of genotyping, were excluded from further 
analysis. Using Haploview  3.32, we showed that the 
genotype frequency distributions in MS patients and 
their parents were in Hardy–Weinberg equilibrium 
(р < 0.05).
TDT was used to obtain the χ2 values characterizing 
the difference between the observed frequencies of in-
heritance of alleles of the HLA-DRB1, CTLA4, TGFB1, 
IL4, CCR5, RANTES, MMP9, and  TIMP1 genes by 
affected children from 100  nuclear families from the 
frequencies expected in the absence of association 
between the allele and the disease. The χ2 value was 
used to calculate the p value (Table  2). We detected a 
significant linkage/association between MS and the 
HLA-DRB1*15 (χ2  =  5.7, p  =  0.02) and MMP9*(–1562)
С (χ2  =  4.1, p  =  0.04) alleles. For the remaining poly-
morphic regions, no significant results were obtained 
(χ2  <  3.8, p  >  0.05). TDT did not detect the linkage/
association of any studied polymorphism with MS in 
male and female groups separately.
Table  3 lists the results of the AFBAC analysis of 
MS association with the examined polymofphic alle-
les. By comparing the allele frequency in affected chil-
dren with that in the control group consisting of the 
alleles belonging to their mothers and fathers and not 
transmitted to their children, we detected a signifi-
cant MS association only with the HLA-DRB1*15 allele 
(p = 0.02), but not with the alleles of other genes. 
Despite the fact that the family-based association 
analysis has a number of advantages over the popula-
tion-based analysis, such investigations remain rela-88 | ACTA NATURAE |  VOL. 3  № 1 (8)  2011
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tively rare around the world. This is particularly true 
for Russia due to the complexity of collecting nuclear 
family data. Along with the issue of incomplete fami-
lies, cases of false paternity are of considerable quan-
tity. Thus, we had to exclude four families out of the 
initial 104  families in the study.
The genes whose participation in the development 
of MS was studied in this work can be divided into two 
groups, with respect to the extent they were previous-
ly investigated in Russians. The HLA-DRB1, CTLA4, 
TGFB1, and CCR5 genes can be referred to the first 
group; we had previously analyzed MS association with 
the polymorphism of the above genes using the case–
control method with unrelated individuals as controls. 
The second group included the IL4, RANTES, MMP9, 
and  TIMP1 genes, which had not previously been stud-
ied in details.
The replication (validation) of the data on the as-
sociation of a particular gene with the disease on in-
dependent samples is now considered as a necessary 
condition for the results to be accepted by the scientific 
community. This requirement was thoroughly satisfied 
in our study for the genes from the first group. The MS 
association with DRB1*15 HLA class  II allele in Rus-
sians, which was revealed by TDT and  AFBAC, had 
been shown earlier in population-based studies [36, 
37]. On the other hand, we observed no MS association 
with alleles of the CTLA4, TGFB1, and  CCR5 genes 
neither while carrying out the family-based analysis 
in this study nor while carrying out the case-control 
analysis on independent groups of unrelated individu-
als [37–39].
We had previously used the TDT method to show 
the MS linkage/association of DRB1*15 HLA class II al-
lele in children and adolescents (so-called juvenile MS, 
with onset below the age of 15) [11]. Since only DNA 
samples obtained from 39  nuclear families were avail-
able, we simulated the analysis of the bi-allelic locus 
and compared the carriers of the DRB1*15 allele with 
allele non-carriers: i.e., the carriers of all other alleles 
of the DRB1 gene. In the present study, we first ana-
lyzed the MS linkage and association with all the alleles 
of multi-allele polymorphism of the HLA-DRB1 gene 
in Russians and confirmed MS association and linkage 
Table 1. Polymorphisms of the analyzed genes, genotyping methods, and primers used
Gene Polymorphism SNP ID Analysis method 
(reference) PCR primers (restrictase used)
HLA-DRB1
Allele 01–18 groups, cor-
responding to DR1–DR18 
specificities
– SSP-PCR From the kit for amplification of HLA-DRB1  
(AO DNA Technology, Russia)
CTLA4 SNP 49A>G
(17Thr → Ala) rs231775 PCR RFLP 
[34]**
5’-AAGGCTCAGCTGAACCTGGT and  
5’-CTGCTGAAACAAATGAAACCC[BstEII]
TGFB1 SNP -509C>T rs1800469 SSP-PCR
5’-GGGCAACAGGACACCTGAA-3’(SSP T),5’-
GGGCAACAGGACACCTGAG-3’ (SSP C), and 
5’-AAGGCATGGCACCGCTTCTG-3’
(common forward primer)
IL4 SNP -590C>T rs2243250 SSP-PCR
5’-CTAAACTTGGGAGAACATTGTC-3’ (SSP C),  
5’-CTAAACTTGGGAGAACATTGTT 3’ (SSP T),  
and 5’-AGTACAGGTGGCATCTTGGAAA-3’ 
(common reverse primer)
CCR5 (w → d) (”wild type” → dele-
tion of 32 bp) – PCR 5’-AGGTCTTCATTACACCTGCAGC-3’  
and 5’-CTTCTCATTTCGACACCGAAGC-3’
RANTES SNP -403G>A rs2107538 SSP-PCR
5’-CCATGGATGAGGGAAAGGAGG-3’ (SSP G), 
5’-CCATGGATGAGGGAAAGGAGA-3’ (SSP A), 
and 5’-AGGGAAGGGGTCCTCCTCAG-3’
(common reverse primer)
MMP9 SNP -1562C>T C rs3918242 PCR RFLP 5’-GCCTGGCACATAGTAGGCCC-3’ and 
5’-CTTCCTAGCCAGCCGGCATC-3’ [SphI]
TIMP1 SNP 372C>T rs4898 SSP-PCR
5’-CTGTTCAGGGAGCCACG-3’ (ASP SSP C), 
5’-CTGTTCAGGGAGCCACA-3’ (SSP  T), and 
5’-AGCGAGGAGTTCTCATTGCT-3’
(common forward primer)
* All SNP positions are presented relative to transcription start sites, with the exception of CTLA4 49A>G, where 49 is 
the position relative to the translation start site.
** The reference is given for the case when the technique described was used.
Note. SSP–site-specific primer; RFLP–restriction fragment length polymorphism.RESEARCH ARTICLES
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Table  2. Transmission of polymorphous alleles of HLA-DRB1,CTLA4, TGFB1, IL4, CCR5, RANTES, MMP9, and TIMP1 
genes from healthy heterozygous parents to children with multiple sclerosis in100 nuclear families (analysis by TDT)*
Gene Allele
Number of 
heterozygous 
parents
Transmitted, 
cases
Non-
transmitted, 
cases
χ2 p
DRB1
01 35 22 13 2.3 > 0.05
04 34 16 18 0.2 > 0.05
07 36 18 18 0.0 > 0.05
08 12 4 8 1.3 > 0.05
11 53 24 29 0.5 > 0.05
13 37 18 19 0.1 > 0.05
15 70 45 25 5.7 0.02
16 11 3 8 2.3 > 0.05
17 46 20 26 0.8 > 0.05
CTLA4
A
104
51 53
0.04 > 0.05
G 53 51
TGFB1
C
101
48 53
0.3 > 0.05
T 53 48
IL4
C
69
32 37
0.4 > 0.05
T 37 32
CCR5
w
39
20 19
0.03 > 0.05
d 19 20
RANTES
G
63
31 32
0.1 > 0.05
A 32 31
MMP9
C
48
31 17
4.1 0.04
T 17 31
TIMP1**
C
49
28 21
0.5 > 0.05
T 21 28
* Data for the DRB1*09, *10, *12, and *14  alleles, the number of carriers of which among healthy parents is ≤  5 (2.5%), 
are insignificant and are not listed in Tables  2  and  3.
** Since the TIMP1 gene is located on the X-chromosome, we considered the transmission of alleles to affected children 
only from heterozygous mothers.
with the DRB1*15 allele, regardless of the age of onset.
The data on MS association with polymorphism of 
CCR5 (w→d) [40–42] and  SNP 49A>G of CTLA4 in oth-
er Caucasians are controversial [43–45], whereas no MS 
association with SNP –509C>T of TGFB1 has been ob-
served [46–48]. As for the DRB1 gene, it appears to be 
the major genetic risk factor for MS in all Caucasians, 
although MS associations with other allelotypes, rather 
than DRB1*15, have been detected in some populations 
in the Mediterranean [2].
The absence of individual MS association with pol-
ymorphisms in the CTLA4, TGFB1, and  CCR5 genes 
does not exclude their possible role as genetic risk fac-
tors for the disease, in combination with several oth-
er alleles/genotypes. Indeed, the alleles CTLA4*49G, 
TGFB1*(–509)С, and  CCR5*d are the parts of MS-
predisposing bi- and tri-allelic combinations with al-
leles of other genes found using the APSampler algo-
rithm [37]. Combinations of alleles including the CTLA4 
and  TGFB1 genes that are associated with MS were 
detected in other studies [2]. The question of whether 
the association of allelic combinations with polygenic 
diseases can be determined either by the additive con-
tribution of separate genes or by gene-gene interac-
tions remains open. 
Among the genes first time investigated using the 
TDT method in Russian MS patients, nonrandom trans-
mission of the MMP9*(–1562)C allele from healthy par-
ents to the affected child was shown. The results ob-
tained for other Slavic populations (in Serbia [49] and 
the Czech Republic [50]) showed a significant decrease 
in T-allele frequency in MS patients as compared with 
healthy individuals and are in agreement with our data 
that allele C participates in the development of MS. 
However, these results were not confirmed with the 
AFBAC method in our study, whereas T  allele in Poles 90 | ACTA NATURAE |  VOL. 3  № 1 (8)  2011
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[51] acts as a MS predisposing allele. Thus, the issue of 
the participation of the MMP9 gene in the appearance 
of MS predisposition requires additional studies.
We did not reveal MS association with polymor-
phisms of the IL4, RANTES, and  TIMP1 genes with 
the two methods of family-based analysis. According to 
published data SNP –590C>T of the IL4 gene is associ-
ated with MS in Germans, particularly in females [52]. 
In Spaniards, SNP 33C>T of the IL4 gene is associated 
with MS, demonstrating a total linkage disequilibrium 
with SNP -590C>T of this gene [53]. The results of a 
study carried out in Iranians are in agreement with our 
data on the absence of MS linkage/association with 
the 33C>T region of the IL4 gene [54]. Association of 
RANTES SNP –403G>A with MS remains insufficient-
ly studied; however, association of this polymorphism 
with MS was observed in Caucasians in the single study 
found, [55]. Data concerning the analysis of the 372C>T 
region of the TIMP1 gene has not been published.
CONCLUSIONS
In this study, we used the methods of family-based 
analysis of linkage and/or association, which allow to 
eliminate or minimize the effects of a possible ethnic 
heterogeneity of the studied sample in the obtained re-
sults. The role of the HLA-DRB1, CTLA4, TGFB1, IL4, 
CCR5, RANTES, MMP9, and TIMP1 genes polymor-
phisms in MS development in ethnic Russians was ana-
lyzed. The data obtained by TDT are evidence of MS 
linkage/association with the DRB1*15 and  MMP9*(–
1562)С alleles; association of DRB1*15 with the disease 
was confirmed by the AFBAC method. The present 
study shows the efficiency of the family-based ap-
proach in the study of polygenic diseases. 
This work was supported by the Russian Foundation 
for Basic Research (grants № 05-04-48982 and  
08-04-01834).
Table  3. Family-based analysis of MS association with alleles of  HLA-DRB1, CTLA4, TGFB1, IL4, CCR5, RANTES, 
MMP9, and TIMP1 genes in  100 nuclear families carried out using the AFBAC method
Gene Allele Number (%) of alleles in MS patients 
(n = 200)
Number (%) of alleles that were not 
transmitted to affected children by 
parents (n = 200)
p
DRB1
01 25 (12.5) 6 (8) > 0.05
04 22 (11.0) 25 (12.5) > 0.05
07 22 (11.0) 22 (11.0) > 0.05
08 5 (2.5) 9 (4.5) > 0.05
11 25 (12.5) 30 (15) > 0.05
13 21 (10.5) 22 (11) > 0.05
15 50 (25) 30 (15) 0.02
16 3 (1.5) 8 (4) > 0.05
17 22 (11) 28 (14) > 0.05
CTLA4
A 113 (57) 103 (52)
> 0.05
G 87 (43) 97 (48)
TGFB1
C 132 (66) 137 (69)
> 0.05
T 68 (34) 63 (31)
IL4
C 158 (79) 165 (83)
> 0.05
T 42 (21) 35 (17)
CCR5
w 179 (90) 178 (89)
> 0.05
d 21 (10) 22 (11)
RANTES
G 163 (82) 164 (82)
> 0.05
A 37 (18) 36 (18)
MMP9
C 120 (60) 105 (53)
> 0.05
T 80 (40) 95 (47)
TIMP1
C 88 (56) 80 (55)
> 0.05
T 68 (44) 65 (45)RESEARCH ARTICLES
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